Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F10 | P00742 | 1/20 | 0.76 |
| ▸ | TPSAB1 | Q15661 | 18/20 | 0.57 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.56 |
| ▸ | PRSS2 | P07478 | 1/20 | 0.56 |
| ▸ | PRSS3 | P35030 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL301845 | 0.95 | F10 (0.67) | F10TPSAB1PRSS1PRSS2PRSS3 | |
| SCHEMBL972001 | 0.90 | F10 (0.62) | F10TPSAB1PRSS1PRSS2PRSS3 | |
| Trifluoroacetic Acid SCHEMBL1381804 | 0.90 | F10 (0.80) | F10TPSAB1PRSS1PRSS2PRSS3 | |
| Trifluoroacetic Acid SCHEMBL1382400 | 0.84 | TPSAB1 (0.58) | F10TPSAB1 | |
| SCHEMBL4408248 | 0.84 | F10 (0.71) | F10TPSAB1PRSS1PRSS2PRSS3 | |
| SCHEMBL6808390 | 0.84 | F10 (0.55) | F10TPSAB1PRSS1PRSS2PRSS3 | |
| SCHEMBL302010 | 0.80 | F10 (0.51) | F10TPSAB1PRSS1PRSS2PRSS3 | |
| SCHEMBL15788530 | 0.80 | F10 (0.51) | F10TPSAB1PRSS1PRSS2PRSS3 | |
| SCHEMBL6807311 | 0.79 | F10 (0.49) | F10TPSAB1PRSS1PRSS2PRSS3 | |
| SCHEMBL18652788 | 0.79 | F10 (0.49) | F10TPSAB1PRSS1PRSS2PRSS3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040192734-A1 | 4-(3-aminomethylphenyl)piperidin-1-yl]-[5-(2-fluorophenylethynyl)furan-2-yl]-methanone as an inhibitor of mast cell tryptase | AVENTIS PHARMACEUTICALS INC. (US) | 2004-09-30 | — | — | US | disclosed |
| WO-2004060884-A1 | [4-(3-AMINOMETHYLPHENYL) PIPERIDIN-1-YL]- [5-(2-FLUOROPHENYLETHYNYL)FURAN-2-YL]-METHANONE AS AN INHIBITOR OF MAST CELL TRYPTASE | AVENTIS PHARMACEUTICALS INC. (US) | 2004-07-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040192734-A1 | 4-(3-aminomethylphenyl)piperidin-1-yl]-[5-(2-fluorophenylethynyl)furan-2-yl]-methanone as an inhibitor of mast cell tryptase | CMA1, TPSB2, TPSAB1 | F10 488/4885TPSAB1 3/4885PRSS1 30/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.